Actively Recruiting
Refining Local-Regional Therapy for IBC
Led by Dana-Farber Cancer Institute · Updated on 2025-12-29
50
Participants Needed
1
Research Sites
391 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This Feasibility study is trying to determine: * If Lymphoscintigraphy (imaging of the lymphatic drainage patterns) is effective in demonstrating the drainage to the sentinel lymph nodes in patients with inflammatory breast cancer. * The likelihood of identifying the sentinel lymph nodes in the operating room, using both blue dye and the radioactive substance used for lymphoscintigraphy. * The incidence of lymphedema (arm swelling which occurs after lymph node surgery) in women with inflammatory breast cancer * Outcomes for women with inflammatory breast cancer, whether or not the sentinel lymph nodes can be identified.
CONDITIONS
Official Title
Refining Local-Regional Therapy for IBC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women age 18 years or older
- Diagnosis of Stage III inflammatory breast cancer (cT4d cN0-2) confirmed by biopsy
- Symptoms appeared within 6 months or less before diagnosis
- Breast shows erythema, edema, peau d'orange, and/or warmth involving at least one-third of the breast
- ECOG performance status 2 or better
- Ability to understand and sign informed consent and comply with study procedures, including baseline research biopsy (or approved waiver if biopsy is not safe)
You will not qualify if you...
- Started pre-operative or neoadjuvant therapy before registration
- Stage IV (metastatic) breast cancer
- Positive contralateral axillary lymph nodes found on standard imaging or biopsy
- Confirmed distant disease on staging studies within 42 days of diagnosis
- Contralateral invasive breast cancer with axillary involvement is excluded; in-situ carcinoma or contralateral breast cancer without axillary involvement is allowed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
F
Faina Nahklis, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here